文献速递乳腺CTMRPET

高分辨率半导体PET/CT与MRI评估乳腺癌范围对比

Utility of high-resolution semiconductor positron emission tomography/computed tomography in the assessment of breast cancer extent: comparison with magnetic resonance imaging.
PubMed 文献 · Br J Radiol · 2026-01-01

回顾性纳入77例患者共84个乳腺癌,均行俯卧位全身SiPM PET/CT与动态MRI,排除新辅助化疗。以正常乳腺SUVmean为基础设定四个FDG摄取阈值,将半自动肿瘤大小与病理大小比较并按月经状态与Ki-67分层。1.5SUVmean+2SD与MRI的图像-病理大小比无显著差异且一致率相当;绝经前该阈值更优(60.6%),绝经后MRI更优(61.2%),高Ki-67均为62.2%。

要点

  • 绝经前乳腺癌范围评估可参考1.5SUVmean+2SD阈值,与MRI一致性相当。
  • 绝经后患者MRI病理一致率更高(61.2%),报告范围时优先参考MRI。
  • PET/CT未能显示2个病灶,需警惕假阴性,不可单独用于排除病变。

核心结论

  • 俯卧位WB SiPM PET/CT的1.5SUVmean+2SD阈值对乳腺癌范围评估与MRI诊断效能相当,尤其适用于绝经前患者。
  • 绝经后患者中MRI仍是最佳范围评估手段,两者在高Ki-67肿瘤中一致性最高。

研究设计与样本

  • 回顾性研究,纳入77例患者共84个乳腺癌,均接受俯卧位WB SiPM PET/CT与动态MRI,排除接受新辅助化疗者。
  • 以病理肿瘤大小为参考标准;PET/CT基于正常乳腺SUVmean和SD定义四个肿瘤摄取阈值。

诊断标准与关键数值

  • 四个FDG摄取阈值分别为SUVmean+2SD、SUVmean+3SD、1.5SUVmean+2SD、1.5SUVmean+3SD,基于正常乳腺组织SUVmean与SD。
  • MRI与1.5SUVmean+2SD的图像-病理肿瘤大小比无显著差异,所有MRI及各SUV阈值测量均与病理大小强相关。
  • 1.5SUVmean+2SD在绝经前患者病理一致率为60.6%(P<.05)且优于MRI;MRI在绝经后患者为61.2%。
  • 高Ki-67组中1.5SUVmean+2SD与MRI病理一致率均为62.2%,为各组最高。

临床应用与阅片要点

  • 绝经前患者评估范围时,可参考正常乳腺1.5SUVmean+2SD阈值进行PET/CT半自动测量。
  • 绝经后患者报告病变范围时仍以动态MRI为优先依据。
  • PET/CT有漏显示病灶可能,需结合MRI和病理,不能仅凭PET/CT阴性排除范围。

局限性

  • 研究为回顾性设计,存在选择偏倚可能。
  • 纳入患者均排除接受新辅助化疗,结论外推至新辅助化疗人群受限。
  • PET/CT未能显示2个病灶,提示该评估方法并非对所有病灶均能显示。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aims to compare the potential of whole-body silicon photomultiplier positron emission tomography/computed tomography (WB SiPM PET/CT) in the prone position with dynamic magnetic resonance imaging (MRI) in determining the extent of breast cancer.

METHODS: This retrospective study included 77 patients with 84 breast cancers who underwent both PET/CT and MRI, excluding those who received neoadjuvant chemotherapy. Four tumor thresholds for 18F-fluorodeoxyglucose uptake were defined based on the mean standardized uptake value (SUVmean) and standard deviation (SD) of normal breast tissue: SUVmean+2SD, SUVmean+3SD, 1.5SUVmean+2SD, and 1.5SUVmean+3SD. Semiautomatic measurements of tumor size for each threshold and MRI were compared against pathological tumor size and analyzed by menopausal status and Ki-67 expression.

RESULTS: PET/CT failed to visualize 2 lesions. No significant differences in the image-to-pathological tumor size ratio were observed between MRI and the 1.5SUVmean+2SD. All MRI and SUV threshold measurements exhibited strong correlations with pathological size. The 1.5SUVmean+2SD demonstrated the highest pathological concordance rate, comparable to MRI. Subgroup analysis revealed that the 1.5SUVmean+2SD was superior for premenopausal patients (60.6%, P < .05), while MRI excelled in postmenopausal patients (61.2%). Both 1.5SUVmean+2SD and MRI achieved the highest concordance rates (62.2%) in the high-Ki-67 group.

CONCLUSIONS: The 1.5SUVmean+2SD of prone WB SiPM PET/CT offers a diagnostic performance equivalent to MRI for assessing breast cancer extent, particularly in premenopausal patients, while MRI remains optimal for postmenopausal patients. Both modalities are also highly effective in high Ki-67 tumors.

ADVANCES IN KNOWLEDGE: These findings highlight the potential of high-resolution semiconductor PET/CT for assessing breast cancer extent.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Miyamoto, Yoshizako, Kuroda, et al. Utility of high-resolution semiconductor positron emission tomography/computed tomography in the assessment of breast cancer extent: comparison with magnetic resonance imaging. Br J Radiol. 2026. PMID: 42377285. doi:10.1093/bjr/tqag157

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。